Related Experiment Videos

Carvedilol: therapeutic application and practice guidelines

B E Bleske1, E M Gilbert, M A Munger

  • 1University of Michigan College of Pharmacy, Ann Arbor, USA.

Pharmacotherapy
|August 6, 1998
PubMed

Insights

Carvedilol, a beta-blocker, effectively reduces mortality and disease progression in heart failure patients when added to standard treatments. It is well-tolerated and improves quality of life, with clinical guidelines available for its use.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure progression is linked to neurohormonal activation and impaired myocardial energetics.
  • Therapies targeting these mechanisms offer significant benefits.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of carvedilol in heart failure management.
  • To provide clinical guidelines for carvedilol use.

Main Methods:

  • Carvedilol, a nonselective beta-adrenergic blocker with vasodilating properties, was administered to heart failure patients.
  • Outcomes assessed included mortality, disease progression, and quality of life.

Main Results:

  • Carvedilol addition to standard therapy significantly reduced mortality.
  • The drug slowed heart failure progression and improved patient quality of life.
  • Carvedilol was well-tolerated when administered per guidelines.

Conclusions:

  • Carvedilol is a beneficial therapy for heart failure, improving survival and quality of life.
  • Adherence to recommended guidelines ensures good tolerability.
  • Clinical guidelines are provided to support optimal use of carvedilol.

Related Concept Videos